The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
Takeda will soon report phase III results with its dengue fever vaccine, while Regenxbio needs an improvement with its cholesterol-lowering gene therapy candidate,…
Krystal Biotech shares have surged 53% so far this week on gene therapy data in two patients, but rivals are waiting in the wings.
Early data are due for Krystal Biotech’s epidermolysis bullosa project and Uniqure’s haemophilia B candidate.
As data on Amicus Therapeutics' clinical-stage Pompe disease candidate roll in, the group locks up preclinical gene therapy assets.
The sellside’s protestations aside, results at the World Muscle meeting position risdiplam and AVXS-101 as serious challengers to Spinraza in spinal muscular atrophy.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…